Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Association between timing of dialysis initiation and clinical outcomes in the paediatric population: an ESPN/ERA-EDTA registry study.

Authors:
Evgenia Preka Marjolein Bonthuis Jerome Harambat Kitty J Jager Jaap W Groothoff Sergey Baiko Aysun K Bayazit Michael Boehm Mirjana Cvetkovic Vidar O Edvardsson Svitlana Fomina James G Heaf Tuula Holtta Eva Kis Gabriel Kolvek Linda Koster-Kamphuis Elena A Molchanova Marina Muňoz Gisela Neto Gregor Novljan Nikoleta Printza Emilija Sahpazova Lisa Sartz Manish D Sinha Enrico Vidal Karel Vondrak Isabelle Vrillon Lutz T Weber Marcus Weitz Ilona Zagozdzon Constantinos J Stefanidis Sevcan A Bakkaloglu

Nephrol Dial Transplant 2019 11;34(11):1932-1940

Department of Pediatric Nephrology, Gazi University, Ankara, Turkey.

Background: There is no consensus regarding the timing of dialysis therapy initiation for end-stage kidney disease (ESKD) in children. As studies investigating the association between timing of dialysis initiation and clinical outcomes are lacking, we aimed to study this relationship in a cohort of European children who started maintenance dialysis treatment.

Methods: We used data on 2963 children from 21 different countries included in the European Society of Pediatric Nephrology/European Renal Association-European Dialysis and Transplant Association Registry who started renal replacement therapy before 18 years of age between 2000 and 2014. We compared two groups according to the estimated glomerular filtration rate (eGFR) at start: eGFR ≥8 mL/min/1.73 m2 (early starters) and eGFR <8 mL/min/1.73 m2 (late starters). The primary outcomes were patient survival and access to transplantation. Secondary outcomes were growth and cardiovascular risk factors. Sensitivity analyses were performed to account for selection- and lead time-bias.

Results: The median eGFR at the start of dialysis was 6.1 for late versus 10.5 mL/min/1.73 m2 for early starters. Early starters were older [median: 11.0, interquartile range (IQR): 5.7-14.5 versus 9.4, IQR: 2.6-14.1 years]. There were no differences observed between the two groups in mortality and access to transplantation at 1, 2 and 5 years of follow-up. One-year evolution of height standard deviation scores was similar among the groups, whereas hypertension was more prevalent among late initiators. Sensitivity analyses resulted in similar findings.

Conclusions: We found no evidence for a clinically relevant benefit of early start of dialysis in children with ESKD. Presence of cardiovascular risk factors, such as high blood pressure, should be taken into account when deciding to initiate or postpone dialysis in children with ESKD, as this affects the survival.

Download full-text PDF

 Source
http://dx.doi.org/10.1093/ndt/gfz069DOI Listing
November 2019

Publication Analysis

Top Keywords

timing dialysis
12
dialysis initiation
8
clinical outcomes
8
initiation clinical
8
association timing
8
dialysis
5
pediatric nephrology/european
4
society pediatric
4
european society
4
included european
4
nephrology/european renal
4
renal association-european
4
dialysis transplant
4
countries included
4
association-european dialysis
4
transplant association
4
treatmentmethods data
4
children started
4
european children
4
cohort european
4

Keyword Occurance

Similar Publications

Dialysis disequilibrium on CKRT: avoiding the steep slippery slope.

Authors:
Jessica L Stahl Russell S Whelan Jordan M Symons

Pediatr Nephrol 2021 Apr 9. Epub 2021 Apr 9.

Division of Nephrology, Seattle Children's Hospital, Seattle, WA, USA.

Background: Current guidelines for initiation of kidney replacement do not include specific recommendations for prescription parameters and monitoring.

Case Outline: A 16-year-old girl presented with kidney failure with creatinine of 19.8 mg/dL and BUN of 211 mg/dL. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

The role of antirheumatics in patients with COVID-19.

Authors:
Christoffer B Nissen Savino Sciascia Danieli de Andrade Tatsuya Atsumi Ian N Bruce Randy Q Cron Oliver Hendricks Dario Roccatello Ksenija Stach Mattia Trunfio Évelyne Vinet Karen Schreiber

Lancet Rheumatol 2021 Mar 30. Epub 2021 Mar 30.

Danish Hospital for Rheumatic Diseases, University of Southern Denmark, Sønderborg, Danmark.

The COVID-19 pandemic has resulted in more than 2 million deaths globally. Two interconnected stages of disease are generally recognised; an initial viral stage and a subsequent immune response phase with the clinical characteristics of hyperinflammation associated with acute respiratory distress syndrome. Therefore, many immune modulators and immunosuppressive drugs, which are widely used in rheumatological practice, have been proposed as treatments for patients with moderate or severe COVID-19. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Pharmacokinetics and Safety of Lefamulin After Single Intravenous Dose Administration in Subjects with Impaired Renal Function and those Requiring Hemodialysis.

Authors:
Wolfgang W Wicha Thomas C Marbury James A Dowell Jared L Crandon Cathie Leister James Ermer Steven P Gelone

Pharmacotherapy 2021 Apr 2. Epub 2021 Apr 2.

Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania, USA.

Study Objective: Lefamulin is a novel IV and oral pleuromutilin recently approved for the treatment of community-acquired bacterial pneumonia (CABP). Given that renal comorbidities are common in patients admitted for CABP, understanding the pharmacokinetics of lefamulin in the face of severe renal impairment, including those requiring hemodialysis, is needed.

Design: Open-label, Phase-1 pharmacokinetic study SETTING: Research Study Center PATIENTS: Twenty-three matched subjects were included, seven with "Normal" renal function (creatinine clearance >90 mL/min), eight with "Severe" renal impairment (glomerular filtration rate <30 mL/min/1. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Continuous Renal Replacement Therapy (CRRT) for Nonrenal Indications among Critically Ill Children with Malignancy.

Authors:
Wun Fung Hui Kam Lun Hon Alexander K C Leung Karen Ka Yan Leung Shu Wing Ku Frankie W T Cheng

Case Rep Pediatr 2021 13;2021:6660466. Epub 2021 Mar 13.

Department of Paediatrics and Adolescent Medicine, The Hong Kong Children's Hospital, Hong Kong.

The role of continuous renal replacement therapy (CRRT) has been expanding beyond support for acute kidney injury (AKI) in recent years. Children with malignancy are particularly at risk of developing conditions that may require CRRT. We reported three children with malignancy who received CRRT for non-AKI indications. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Timing of kidney replacement therapy initiation in acute kidney injury.

Authors:
Alejandro Y Meraz-Muñoz Sean M Bagshaw Ron Wald

Curr Opin Nephrol Hypertens 2021 May;30(3):332-338

Division of Nephrology, St. Michael's Hospital and the University of Toronto, Toronto, Ontario.

Purpose Of Review: Over the past 5 years, four major randomized controlled trials were published informing our practice on the optimal timing for kidney replacement therapy (KRT) initiation in critically ill patients with acute kidney injury (AKI). In this review, we summarize the main findings of these trails and discuss the knowledge gaps that still need to be addressed.

Recent Findings: Four recent trials compared early versus delayed initiation of KRT in critically ill patients with acute kidney injury. Read More

View Article and Full-Text PDF
May 2021
Similar Publications